Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 23 papers were listed this time. Here's a few in our areas of research interest:
Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev. 2013 Apr 27;3(1):11. [Epub ahead of print] PubMed PMID: 23621944.
Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013 Apr 27;13(1):190. [Epub ahead of print] PubMed PMID: 23621902.
Wielage RC, Bansal M, Andrews JS, et al. Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Appl Health Econ Health Policy. 2013 Apr 25. [Epub ahead of print] PubMed PMID: 23616247.
Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer. 2013 Apr 20. [Epub ahead of print] PubMed PMID: 23611660.
